FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385751346> ?p ?o ?g. }

• W4385751346 endingPage "975" @default.
• W4385751346 startingPage "959" @default.
• W4385751346 abstract "Introduction The prostate-specific membrane antigen (PSMA) targeted radioligand therapy (PRLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients has generated significant interest among the oncologic community, with several publications documenting good response rates and survival benefits with low toxicity profiles.Areas covered Indications, patient preparation, dose administration, post-treatment imaging, dosimetry, and side effect profiles of 177Lu-PSMA-617 are discussed in this article. We also discuss results from prospective studies, major retrospective studies, meta-analyses, clinical trials, and mentioned major ongoing clinical trials on PRLT. We have also portrayed our own experiences and future perspectives on PRLT.Expert opinion For PRLT, PSMA-617 and PSMA-I&T molecules have revolutionized the theranostic approach in the management of advanced prostate cancer, with solid backing from several published articles showing favorable outcomes and an excellent safety profile of 177Lu-PSMA-617. Improvement in quality of life and survival was seen in the majority of mCRPC patients after 177Lu-PSMA-617 PRLT. Patients with features of good performance or asymptomatic status, only lymph node metastases, high PSMA-expressing lesions with no discordant FDG-avid lesions demonstrate longer survival as compared to patients with features of poor performance status, symptomatic, hepatic, brain, and skeletal metastases, discordant PSMA-avid and FDG-avid lesions, respectively. Docetaxel and cabazitaxel are approved treatments for mCRPC patients. 177Lu-PSMA-617 is approved as a third-line systemic treatment for mCRPC patients with failure to respond to androgen receptor pathway inhibitors and docetaxel therapy. PRLT is a safe and effective alternative to cabazitaxel (third-line systemic treatment), but it has a higher cost. 177Lu-PSMA-617 could be a more efficient therapeutic option for mCRPC patients as first-line or combined therapy, and it may be a useful therapeutic option for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) patients. Several clinical studies and clinical trials on PRLT are currently underway. In the future, the results of these trials will be helpful in evolving treatment strategies for prostate cancer patients." @default.
• W4385751346 created "2023-08-12" @default.
• W4385751346 creator A5007636610 @default.
• W4385751346 creator A5054315303 @default.
• W4385751346 date "2023-08-28" @default.
• W4385751346 modified "2023-09-27" @default.
• W4385751346 title "PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects" @default.
• W4385751346 cites W1546799663 @default.
• W4385751346 cites W1904433804 @default.
• W4385751346 cites W1977316337 @default.
• W4385751346 cites W2048150595 @default.
• W4385751346 cites W2105337740 @default.
• W4385751346 cites W2170337253 @default.
• W4385751346 cites W2175765437 @default.
• W4385751346 cites W2278392405 @default.
• W4385751346 cites W2302508993 @default.
• W4385751346 cites W2303817381 @default.
• W4385751346 cites W2304896218 @default.
• W4385751346 cites W2336971346 @default.
• W4385751346 cites W2341926107 @default.
• W4385751346 cites W2397136240 @default.
• W4385751346 cites W2523192478 @default.
• W4385751346 cites W2525124727 @default.
• W4385751346 cites W2532226140 @default.
• W4385751346 cites W2596023559 @default.
• W4385751346 cites W2753764866 @default.
• W4385751346 cites W2756840809 @default.
• W4385751346 cites W2765669897 @default.
• W4385751346 cites W2771847508 @default.
• W4385751346 cites W2784080506 @default.
• W4385751346 cites W2799931007 @default.
• W4385751346 cites W2800721762 @default.
• W4385751346 cites W2900829249 @default.
• W4385751346 cites W2901319364 @default.
• W4385751346 cites W2903235542 @default.
• W4385751346 cites W2914833937 @default.
• W4385751346 cites W2934758107 @default.
• W4385751346 cites W2937409539 @default.
• W4385751346 cites W2943362136 @default.
• W4385751346 cites W2945708305 @default.
• W4385751346 cites W2945915427 @default.
• W4385751346 cites W2969742213 @default.
• W4385751346 cites W2979393286 @default.
• W4385751346 cites W2982490110 @default.
• W4385751346 cites W2988034537 @default.
• W4385751346 cites W2990351859 @default.
• W4385751346 cites W2990966824 @default.
• W4385751346 cites W3005616683 @default.
• W4385751346 cites W3015253420 @default.
• W4385751346 cites W3021338686 @default.
• W4385751346 cites W3040491196 @default.
• W4385751346 cites W3044164917 @default.
• W4385751346 cites W3092344805 @default.
• W4385751346 cites W3094362710 @default.
• W4385751346 cites W3097158220 @default.
• W4385751346 cites W3106786206 @default.
• W4385751346 cites W3111149356 @default.
• W4385751346 cites W3112030517 @default.
• W4385751346 cites W3128646645 @default.
• W4385751346 cites W3130934287 @default.
• W4385751346 cites W3132107456 @default.
• W4385751346 cites W3153945848 @default.
• W4385751346 cites W3176208875 @default.
• W4385751346 cites W3190846855 @default.
• W4385751346 cites W3193406140 @default.
• W4385751346 cites W3198220892 @default.
• W4385751346 cites W3211098725 @default.
• W4385751346 cites W3217433724 @default.
• W4385751346 cites W4220893194 @default.
• W4385751346 cites W4221014004 @default.
• W4385751346 cites W4281670341 @default.
• W4385751346 cites W4304630351 @default.
• W4385751346 doi "https://doi.org/10.1080/14737140.2023.2247562" @default.
• W4385751346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37565281" @default.
• W4385751346 hasPublicationYear "2023" @default.
• W4385751346 type Work @default.
• W4385751346 citedByCount "0" @default.
• W4385751346 crossrefType "journal-article" @default.
• W4385751346 hasAuthorship W4385751346A5007636610 @default.
• W4385751346 hasAuthorship W4385751346A5054315303 @default.
• W4385751346 hasConcept C121608353 @default.
• W4385751346 hasConcept C126322002 @default.
• W4385751346 hasConcept C143998085 @default.
• W4385751346 hasConcept C170493617 @default.
• W4385751346 hasConcept C20417620 @default.
• W4385751346 hasConcept C2777511904 @default.
• W4385751346 hasConcept C2777899217 @default.
• W4385751346 hasConcept C2777910003 @default.
• W4385751346 hasConcept C2778971682 @default.
• W4385751346 hasConcept C2780192828 @default.
• W4385751346 hasConcept C2780849966 @default.
• W4385751346 hasConcept C2781190966 @default.
• W4385751346 hasConcept C530470458 @default.
• W4385751346 hasConcept C535046627 @default.
• W4385751346 hasConcept C67847695 @default.
• W4385751346 hasConcept C71924100 @default.
• W4385751346 hasConceptScore W4385751346C121608353 @default.
• W4385751346 hasConceptScore W4385751346C126322002 @default.

• next